$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
What is the average resistance time to regorafenib?
2026-02-01 22:25:32
Check Details
How effective is regorafenib in treating cancer?
2026-02-01 22:25:32
Check Details
What should I do if my platelets fall off after taking Eltrombopag/Eltrombopag for one month?
2026-02-01 22:25:32
Check Details
The latest news on Eltrombopag/Eltrombopag being included in medical insurance
2026-02-01 22:25:32
Check Details
Eltrombopag/Eltrombopag price and purchase channels
2026-02-01 22:25:32
Check Details
Eltrombopag/eltrombopag platelet-raising effect and price
2026-02-01 22:25:32
Check Details
Which patients are suitable for taking Eltrombopag/Eltrombopag ethanolamine tablets?
2026-02-01 22:25:32
Check Details
Is Eltrombopag/Eltrombopag a hormonal drug?
2026-02-01 22:25:32
Check Details
The difference between avatrombopag and eltrombopag/eltrombopag
2026-02-01 22:25:32
Check Details
Pemetinib/Pemetinib is the first generation of targeted drugs
2026-02-01 22:25:32
Check Details
Which tumors can be treated with pemetinib/dabotan?
2026-02-01 22:25:32
Check Details
Is pemetinib/pemetinib marketed in China? Are there any major domestic hospitals?
2026-02-01 22:25:32
Check Details
1
2
...
777
778
779
780
781
782
783
...
10222
10223
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Venetoclax Clinical Guide: Mechanism, Indications, and Originator vs. Generic Comparison
2
Dabrafenib Clinical Guide: Indications, Combination Strategies, and BRAF Inhibitor Comparisons
3
Elagolix Side Effects and Safety Guide
4
Hetrombopag vs. Avatrombopag: Key Differences Between Two Oral TPO-RAs and Safety Considerations
5
Lytenava: The First FDA-Approved Ophthalmic Bevacizumab Formulation
6
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
7
Simtriyo (Centanafadine): World's First NDSRI ADHD Drug Approved by FDA
8
Lipfendra (Enlicitide): The World's First Oral PCSK9 Inhibitor Approved by FDA
9
Orforglipron: The World's First Oral Small-Molecule GLP-1 Receptor Agonist for Weight Management
10
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
11
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
12
FDA Approves Subcutaneous Isatuximab (Sarclisa) for Multiple Myeloma: A New Administration Option